CTI BIOPHARMA CORP (CTIC) Stock Analyst Ratings
USA - NASDAQ:CTIC - US12648L6011 - Common Stock
9.09 USD
0 (0%)
9.09 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 76% to CTIC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.7. This target is 17.66% above the current price.
CTIC was analyzed by 14 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about CTIC.
In the last month the buy percentage fell by 10 points. So the trust of analysts is decreasing.
CTIC was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-24 | JMP Securities | Maintains | Market Perform |
| 2023-05-16 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-05-15 | Stifel | Downgrade | Buy -> Hold |
| 2023-05-11 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-05-11 | Needham | Downgrade | Buy -> Hold |
| 2023-04-19 | Needham | Reiterate | Buy |
| 2023-04-17 | TD Cowen | Maintains | Outperform |
| 2023-03-07 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-06 | Needham | Reiterate | Buy |
| 2023-02-06 | JMP Securities | Reiterate | Market Outperform |
| 2022-10-17 | SVB Leerink | Initiate | Outperform |
| 2022-09-01 | JP Morgan | Initiate | Buy |
| 2022-09-01 | Jefferies | Initiate | Buy |
| 2022-08-09 | JMP Securities | Maintains | Market Outperform |
| 2022-08-09 | Needham | Maintains | Buy |
| 2022-07-07 | Cowen & Co. | Initiate | Outperform |
| 2022-03-02 | JMP Securities | Maintains | Market Outperform |
| 2022-03-02 | Needham | Maintains | Buy |
| 2021-12-01 | Needham | Maintains | Buy |
| 2021-08-09 | BTIG | Initiate | Buy |
| 2021-05-06 | Stifel | Initiate | Buy |
CTI BIOPHARMA CORP / CTIC FAQ
Can you provide the average price target for CTI BIOPHARMA CORP stock?
14 analysts have analysed CTIC and the average price target is 10.7 USD. This implies a price increase of 17.66% is expected in the next year compared to the current price of 9.09.
How do analysts rate CTI BIOPHARMA CORP (CTIC)?
The consensus rating for CTI BIOPHARMA CORP (CTIC) is 75.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.